Hologic The surgical products company reported on Jan. 30 first-quarter earnings of $20.8 million, or 8 cents a share, an increase from year-ago fourth quarter earnings of $10.9 million, or 4 cents. "We are reiterating our OUTPERFORM rating and $24 price target following HOLX's Q1/12 earnings release," Barrington Research analysts wrote in a Feb. 1 report. "We believe the women's health market is an attractive market opportunity. Given that HOLX is the clear leader of this market, investors should be appropriately aligned with this positive trend given the current valuation of HOLX's shares." Hologic was upgraded to a buy from a hold by TheStreet Ratings. Of the 24 analysts who cover the company, 15 rated it a buy. Eight considerd Hologic a hold and one rated it a sell. Hologic has a forward P/E of 13.8. The average among medical supplies companies is 20.92. C.R. Bard ( BCR) and Alere ( ALR) both have lower forward P/Es of 13.29 and 9.55, respectively. TheStreet Ratings gives Hologic a B- grade and $24.37 price target. The stock closed Monday at $20.79 and has risen 18.73% year to date.